ODN 2395 VacciGrade™ - TLR9-based Adjuvant

CpG ODN, Class C (Human/mouse) | Th1 response

ABOUT

CpG ODN, type C (human/mouse) - TLR9-based vaccine adjuvant

ODN 2395 VacciGrade™ is a preclinical formulation of ODN 2395, a class C CpG oligonucleotide (ODN), activator of human and murine Toll-like receptor 9 (TLR9) [1].ODN 2395 is a short synthetic single-stranded DNA molecule containing an entire phosphorothioate backbone (nuclease-resistant) and palindromic CpG motifs capable of forming secondary structures. These CpG motifs mimic microbial DNA and act as immunostimulants via TLR9. 

More details More details

Class C CpG ODNs, such as ODN 2395, combine classes A and B features. They contain a complete phosphorothioate (PS) backbone and a CpG-containing palindromic motif. They strongly induce B cell stimulation as well as IFN-α production in plasmacytoid dendritic cells [2]. Moreover, they generate Th1-dominant immune responses and thus, are potential adjuvants for human vaccines to elicit protective Th1 immunity [2].

InvivoGen's ODN 2395 VacciGrade™ is a strong TLR9 agonist as verified using our HEK-Blue™ TLR9 reporter cell lines expressing human or mouse TLR9 (see figure). Moreover, ODN 2395 VacciGrade™ activates the hTLR9-dependent NF-κB and IRF pathways, as assessed using our THP1-Dual™ hTLR9 reporter cell line expressing two reporter genes, for& the NF-κB-inducible SEAP and IRF-inducible Lucia luciferase, as well as hTLR9 (see figure).

VacciGrade™ is a high-quality pre-clinical grade, suitable for in vivouse.
A standard grade ODN 2395 for in vitro assays is also available.

Get more information about CpG ODNs Classes.

1. Roda JM. et al., 2005. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibodycoated tumor cells. J Immunol. 175(3):1619-27.
2. Jurk M. et al., 2004. C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. Immunobiology. 209(1-2):141-54.

All products are for research use only, and not for human or veterinary use.

VacciGrade™

VacciGrade™ is a high-quality pre-clinical grade, suitable for in vivo studies. VacciGrade™ products are filter-sterilized (0.2 µm) and filled under strict aseptic conditions in a clean room. The absence of  bacterial contamination is assessed by a sterility test using a pharmacopeia-derived assay.

SPECIFICATIONS

Specifications

Source
Synthetic
Target

TLR9

Sequence

5’-tcgtcgttttcggcgcgcgccg-3’ (22 mer)  

Note: Regular letters represent phosphorothioate bonds, bold letters represent CpG dinucleotides

Molecular weight
7048 g/mol
Working concentration

20-50 µg/mouse

Solubility

2 mg/ml in physiological water

Appearance (form)
Lyophilized
Reconstitution buffer
Endotoxin-free physiological water (provided)
Sterility

Sterility guaranteed

Endotoxin

<1 EU/ml (measurement by kinetic chromogenic LAL assay)

Applications

Th1 response, TLR9 activation in cellular assays (tested)

Quality control

Each lot is functionally tested and validated using cellular assays.

CONTENTS

Contents

  • Product: 
    ODN 2395 VacciGrade™
  • Cat code: 
    vac-2395-1
  • Quantity: 
    1 mg
Includes:

10 ml sterile endotoxin-free physiological water (NaCl 0.9%)

Shipping & Storage

  • Shipping method:  Room temperature
  • Storage:

    • -20°C

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

CpG ODNs

Synthetic oligodeoxynucleotides containing unmethylated CpG motifs (CpG ODNs), such as ODN 1018, have been extensively studied as adjuvants [1]. These CpG motifs are present at a 20-fold greater frequency in bacterial DNA compared to mammalian DNA [2]. CpG ODNs are recognized by the Toll-like receptor 9 (TLR9), which is expressed on human B cells and plasmacytoid dendritic cells (pDCs), thereby inducing Th1-dominated immune responses [3]. Pre-clinical studies, conducted in rodents and non-human primates, as well as human clinical trials, have demonstrated that CpG ODNs can significantly improve vaccine-specific antibody responses [1]. Three types of stimulatory CpG ODNs have been identified, types A, B, and C, which differ in their immune-stimulatory activities [4-5]. 

Toll-like receptor 9

The Toll-like Receptor 9 (TLR9) is an endosomal receptor that triggers NF-κB- and interferon regulatory factor (IRF)-mediated pro-inflammatory responses upon the recognition of unmethylated cytosine-phosphorothioate-guanosine (CpG) forms of DNA [6-8]. Unmethylated CpG dinucleotides are a hallmark of microbial (bacterial, viral, fungal, and parasite) DNA, as well as mitochondrial self-DNA [8,9]. These TLR9 agonists can be mimicked by synthetic oligonucleotides containing CpG motifs (CpG ODNs), which have been extensively studied to improve adaptive immune responses in the context of vaccination [6,8].

TLR9 is mainly expressed in subsets of Dendritic Cells and B cells of all mammals. In rodents, but not in humans, TLR9 is also expressed in monocytes and macrophages [8]. The structure of the receptor varies by 24% between human TLR9 (hTLR9) and mouse TLR9 (mTLR9) [8]. They recognize different CpG motifs, the optimal sequences being GTCGTT and GACGTT for hTLR9 and mTLR9, respectively [10].

References:

1. Steinhagen F. et al., 2011. TLR-based immune adjuvants. Vaccine 29(17):3341-55.
2. Hemmi H. et al., 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740-5.
3. Coffman RL. et al., 2010. Vaccine adjuvants: Putting innate immunity to work. Immunity 33(4):492-503.
4. Krug A. et al., 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol, 31(7): 2154-63.
5. Marshall JD. et al., 2005. Superior activity of the type C class of ISS in vitro and in vivo across multiple species. DNA Cell Biol. 24(2):63-72.
6. Kumagai Y. et al., 2008. TLR9 as a key receptor of the recognition of DNA. Adv. Drug. Deliv. Rev. 60(7):795-804.
7. Heinz L.X. et al., 2021. TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9. Nature. 581(7808):316-322.
8. Kayraklioglu N. et al., 2021. CpG oligonucleotides as vaccine adjuvants. DNA Vaccines: Methods and Protocols. Methods in Molecular Biology. Vol. 2197. p51-77.
9. Kumar V., 2021. The trinity of cGAS, TLR9, and ALRs: guardians of the cellular galaxy against host-derived self-DNA. Front. Immunol. 11:624597.
10. Bauer S. et al., 2001. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA, 98(16):9237-42.

DOCUMENTS

Documents

ODN 2395 VacciGrade™

Technical Data Sheet

Safety Data Sheet

Validation Data Sheet

Certificate of analysis

Need a CoA ?

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?